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A case of a patient treated with 
percutaneous edge-to-edge mitral 
valve repair, percutaneous left atrial 
appendage occlusion and implantable 
cardioverter-defibrillator
ABSTRACT
The article presents the case of a 55-year-old woman who suffered from anterior myocardial infarction and 
chronic complications of the underlying disease, heart failure with reduced left ventricular ejection fraction, 
severe secondary mitral regurgitation, and paroxysmal atrial fibrillation. Due to the severity of symptoms, 
which persisted despite the optimal pharmacotherapy, after exclusion of reversible causes, the patient was 
qualified for different advanced percutaneous treatment methods. Within two years from the onset of the 
disease, three percutaneous procedures were performed: mitral valve correction with the MitraClip system, 
left atrial appendage occlusion using the Watchman system, and implantation of cardioverter-defibrillator.
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Introduction
The prevalence of heart failure (HF) concerns 1–2% of 
the adult population in developed countries. Many patients 
have cardiovascular and non-cardiac abnormalities that 
may result in HF. Therefore, the identification of these 
abnormalities should be part of the diagnostic process, 
because many of these causes can be reversible [1–4]. 
Epidemiological data from European studies (ESC-HF pilot 
study) indicate that the 12-month total HF mortality rate in 
hospitalized patients or those under outpatient care was 
17% and 7%, respectively, and the 12-month hospitaliza-
tion rates were 44% and 32% in both groups. In HF patients 
most deaths are caused by cardiovascular events. Sudden 
deaths and deaths related to the disease exacerbation are 
most common in this group of patients [5].
The acute anterior myocardial infarction
The 55-year-old patient was admitted to the Depart-
ment of Cardiology at University Hospital in Bydgoszcz 
on December 15, 2014, due to the acute anterior 
myocardial infarction. The patient had no history of 
chronic diseases, apart from long-term smoking. The 
urgent primary percutaneous coronary intervention of 
the left anterior descending artery with implantation of 
drug-eluting stent (DES) was performed. The proce-
dure was complicated by sudden cardiac arrest in the 
mechanism of asystole with effective cardiopulmonary 
resuscitation. In addition, during the hospitalization, the 
first atrial fibrillation (AF) episode occurred (according 
to the CHA2DS2-VASc score — 4 points, according 
to the HAS-BLED score -1 point). Echocardiographic 
examination revealed: impaired left ventricular systolic 
function with reduced  left ventricular ejection fraction 
(LVEF) of 20-25%, diastolic relaxation dysfunction, se-
vere secondary mitral regurgitation with vena contracta 
(Vc) of 0.9 cm, severe tricuspid valve regurgitation, 
systolic pulmonary artery pressure (SPAP) of 52 mm Hg, 
features of pulmonary hypertension, enlargement of all 
heart chambers: left atrium (LA) 51 mm, left ventricular 
end-systolic diameter (LVESD) of 50 mm, left ventricular 
end-diastolic diameter (LVEDD) of 60 mm, right ventri-
cle (RV) of 40 mm, akinetic apical aneurysm, akinesis 
of the other segments of anterior and interventricular 
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septum. Vitamin K antagonist (warfarin) per patient’s 
choice was introduced to the therapy. The patient was 
discharged in functional class II according to New York 
Heart Association (NYHA) with a further therapeutic plan 
including among others echocardiographic control.
Decompensation of chronic heart failure
Subsequent hospitalization of the patient was associ-
ated with episodes of decompensation of chronic heart 
failure up to NYHA class IV with B-type natriuretic peptide 
(BNP) > 2000 pg/mL. The ECG on admission revealed 
sinus rhythm 88/min, the small progression of R waves in 
V1–V4, no ST–T changes, QRS complex < 110 ms. Echo-
cardiographic parameters were the same as previously. 
The patient underwent coronary angiography which has 
not shown any new lesions in the coronary arteries or rest-
enosis. After the Heart Team consultation, the patient was 
disqualified from the surgical treatment of mitral valve regur-
gitation. Therefore, the patient underwent transthoracic and 
transesophageal echocardiography (TEE) to fully assess 
mitral valve morphology. TEE revealed severe mitral regur-
gitation wave with Vc of 0.9 cm, thickened leaflets of mitral 
valve  with features of limited restriction, mitral wave area 
(MVA) of 3.8 cm2, coaptation depth of 0.8 cm, coaptation 
height of  0.6 cm, length of anterior leaflet 2.6 cm, length of 
posterior leaflet 1.6 cm, severe tricuspid regurgitation wave, 
and thrombus-free left atrium appendage.
Percutaneous edge-to-edge mitral valve 
correction
During the next hospitalization approximately a year 
after myocardial infarction, percutaneous edge-to-edge 
mitral valve correction with the use of the MitraClip 
system was performed without periprocedural com-
plications. Two clips were implanted, resulting in a re-
duction of the mitral regurgitation wave. In the follow-up 
echocardiography, two MitraClip sets were found in the 
normal position without device-related thrombi, and two 
narrow mitral regurgitation waves were observed (Vc 
0.4–0.5 cm). Patients general condition improved after 
the procedure. Due to the above-mentioned procedure, 
dual antiplatelet therapy consisting of aspirin 75 mg 
once daily and clopidogrel 75 mg once daily, with 
warfarin (the patient continued to refuse non-vitamin 
K antagonist anticoagulation due to financial reasons).
Percutaneous left atrial appendage 
occlusion
Another scheduled hospitalization was associated 
with routine follow-up after the previous procedure. Lab-
oratory tests revealed a non-therapeutic International 
Normalized Ratio (INR) index of 6.5 and normocytic 
anaemia (Hgb 9.0 g/dL, MCV 81.5 fL). According to 
the patient from the beginning of the anticoagulation 
treatment, she was not able to obtain stable INRs and 
periodically reported tarry stools. The time in the thera-
peutic range of INR was rated at < 60% for this patient. 
The gastroduodenoscopy revealed a non-bleeding 
vessel (Forrest IIa) in the duodenum. Recalculated 
CHA2DS2-VASc score was 4 points, and HAS-BLED 
score was 3 points. The patient was qualified for left 
atrial appendage occlusion. Intraprocedural TEE did 
not reveal thrombi in the left atrial appendage, and the 
percutaneous occlusion of the left atrial appendage with 
the Watchman system was performed without com-
plications. After the procedure warfarin was stopped, 
while dual antiplatelet therapy was maintained. Control 
echocardiographic studies (transthoracic and transe-
sophageal) performed after the procedure and during 
planned controls showed the correct position of the 
occluder in the left atrial appendage without residual 
leaks or device-related thrombi. This examination 
also revealed the correct position of the previously 
implanted MitraClip sets and moderate double-stream 
mitral regurgitation wave (Vc 0.6 cm). The remaining 
parameters were comparable to the previous study, 
with no improvement in LVEF which remained at the 
level of 20–25%.
Implantation of the cardioverter-
defibrillator
Available ECG monitoring (telemetry or ECG 
Holter) did not reveal any complex ventricular ar-
rhythmias. Due to the clinical picture (post-infarction 
cardiomyopathy, LVEF ≤ 35%, optimal medical ther-
apy (OMT) for more than 3 months (Tab. 1), without 
QRS complex ≥ 130 ms), the patient was qualified for 
implantation of transvenous cardioverter-defibrillator 
(ICD) for the primary prevention of sudden cardiac 
death. During the next hospitalization, ICD (Medtron-
ic Protecta VR, Medtronic 6935M–55 cm lead) was 
implanted in the left subclavian area. The procedure 
Table 1. Optimal pharmacotherapy
Drug and dose [mg]
Aspirin 75 once daily
Ramipril 2.5 once daily
Carvedilol 25 twice daily
Furosemide 40 twice daily
Eplerenone 50 once daily
Atorvastatin 20 once daily
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Table 2. Selected ESC recommendations.
Recommendations Class Level References
In patients with severe secondary mitral regurgitation and LVEF < 30% who remain 
symptomatic despite optimal medical management (including cardiac resynchronization 
therapy (CRT) if indicated) and who have no option for revascularization, the Heart Team 
may consider a percutaneous edge-to-edge procedure or valve surgery after careful 
evaluation for a ventricular assist device or heart transplant according to individual patient 
characteristics
IIb C 6
Left atrial appendage (LAA) occlusion may be considered for stroke prevention in patients 
with AF and contra-indications for long-term anticoagulant treatment (e.g. those with a 
previous life-threatening bleed without a reversible cause)
IIb B 7–9
Primary prevention 
An ICD is recommended to reduce the risk of sudden death and all-cause mortality in 
patients with symptomatic HF (NYHA Class II–III), and an LVEF ≤ 35% despite ≥ 3 months 
of OMT, provided they are expected to survive substantially longer than one year with good 
functional status, and they have:
• ischaemic heart disease (IHD) unless they have had a myocardial infarction in the prior  
40 days
I A 10–12
was carried out without any complications. The con-
trol echocardiography did not show any significant 
changes compared with the previous study. 
Conclusions
The medical history of the patient shows the possibil-
ities of combining OMT and modern invasive methods of 
treatment in cardiology. Due to the severity of the patient’s 
disease, appropriate decisions were made regarding the 
time and type of advanced therapy methods according to 
European Society of Cardiology (ESC) guidelines (Tab. 
2). This is probably one of the few patients in whom, two 
years after the beginning of the disease, three different 
percutaneous treatment methods were used with opti-
mal results. Moreover, since the implementation of the 
above-mentioned methods, the patient was not hospital-
ized due to cardiovascular diseases. The patient is still 
under the control of the outpatient clinic.
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